Retension Pharmaceuticals, a clinical-stage biopharmaceutical company, priced its upsized initial public offering on October 9, 2026. The IPO is expected to generate approximately $45 million in gross proceeds. Its shares will trade on the Nasdaq Capital Market.
The company's lead candidate, RTN-001, is being developed to treat uncontrolled hypertension. The next-generation PDE5 inhibitor is licensed exclusively worldwide from Sanofi.
Separately, Blueprint Medicines, a Sanofi subsidiary, is set to begin layoffs on October 9, 2026. The cuts will affect 229 employees in Cambridge, Massachusetts. The layoffs are scheduled to continue through June 25, 2027. Sanofi completed its acquisition of Blueprint Medicines in July 2025.